Sarah Silbiger/Getty Images/STAT

Leucovorin lacks evidence to use as autism treatment, FDA says

The FDA action represents a retreat from top officials’ earlier insistence that leucovorin could benefit "hundreds of thousands" of children with autism.

By O. Rose Broderick

STAT+ | BioNTech founders to depart, form new mRNA-focused company

Ugur Sahin and Özlem Türeci, who are married, founded the German biotech in 2008. It will continue developing medicines, with a focus on oncology.

By Andrew Joseph

STAT+ | Novo Nordisk is warned by the FDA for failing to report side effects tied to GLP-1 drugs

This is the third time in recent weeks that the FDA has admonished Novo Nordisk for different practices, placing the drugmaker on the defensive.

By Ed Silverman

Adobe

STAT+ | Vertex says its drug successfully reduced marker of kidney disease in late-stage trial

The biotech company is in a three-way race with Otsuka and Vera Therapeutics to treat the condition, called IgA nephropathy.

By Jason Mast

Health AI startup to benefit from $1 billion funding round for Yann LeCun’s AMI

Yann LeCun's Advanced Machine Intelligence raised $1 billion. STAT's Mario Aguilar breaks down the connection to health AI company Nabla.

By Mario Aguilar

STAT+ | Large drugmakers are developing fewer antibiotics, analysis finds

The number of potential antimicrobial treatments being developed by the world’s largest drugmakers nosedived by 35% — from 92 to 60.

By Ed Silverman

Mark Humphrey/AP

Removing race from kidney function algorithm helped more Black patients access transplants

A long-used medical test underestimated the severity of kidney disease in Black patients. New study says with the bias removed, transplant rates are up.

By Anil Oza

STAT+ | Opinion: The Himsification of medicine

Hims has created a new mode of medicine, in which patients are consumers racing to buy into products and practices that feel aspirational and cutting-edge

By Vishal Khetpal